Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

This study is looking for adults aged between 18 and 84 years old who have type 1 diabetes. You would also need to have been diagnosed with heart failure, or be at high risk of developing it. This means your doctor might have found certain signs like specific levels in a blood test, or changes in your heart seen on scans.

To be considered, you also need to be using a continuous glucose monitor (CGM) or be willing to use one during the study. Additionally, your heart failure symptoms should be of a certain level, generally meaning they might affect your daily activities to some extent, but are not so severe that you need constant hospital care.

There are some reasons why you might not be able to join. For example, if you've recently had heart surgery, a heart attack, or had a special heart device fitted within the last month. Also, if you have very severe heart failure that requires mechanical support, you wouldn't be able to take part. The study team will review all your medical information to confirm if you are a good fit.

If you decide to take part, you would be involved in the study for a total of around six months. For four of those months, you would take one tablet each day, which would either be sotagliflozin or a dummy pill (placebo). You won't know which one you're taking, and neither will your medical team, until the study concludes. During this time, you'll have regular hospital visits to check your health, symptoms, and how you're feeling. You'll also be asked to use a continuous glucose monitor (CGM) throughout the study to track your blood sugar levels. There will be various assessments during these visits, including blood tests and possibly heart checks, to see how the treatment is affecting you. Your progress will be carefully monitored to evaluate both the benefits and any potential side effects.